Clinical Trial Update: Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial investigating dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Radboud University Medical Center | Conditions: NSCLC | Phase 3 | Status: UNKNOWN